title: Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.
abstract: Eculizumab is a humanized monoclonal antibody indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). It binds specifically and with high affinity to the complement protein C5, thereby preventing the formation of the terminal complement complex C5b-9, which mediates cell lysis. In patients with PNH, eculizumab inhibits terminal complement mediated intravascular haemolysis. In clinical trials of PNH patients, eculizumab reduced intravascular haemolysis compared with baseline and placebo, as determined by significantly decreased lactate dehydrogenase (LDH) levels. Significant reductions in LDH levels were achieved within the first week of treatment, with near normal levels achieved at week 2 and maintained throughout longer term treatment, including periods of up to 36 months. Eculizumab achieved rapid and sustained efficacy, regardless of baseline LDH levels or platelet counts. In adults with PNH, eculizumab treatment for 26 weeks achieved stabilization of haemoglobin levels in significantly more patients than placebo treatment, and reduced the requirement for packed red cell transfusions to a significantly greater extent than placebo. Half of all patients in the eculizumab group became transfusion independent compared with no patients in the placebo group. Eculizumab was also associated with significant improvements in fatigue and health-related quality-of-life scores in several trials. Over the long term, the survival of PNH patients treated with eculizumab was normalized. Eculizumab was generally well tolerated in clinical trials of PNH patients, including treatment periods of up to 5.5 years. The risk of Neisseria meningitidis is increased with eculizumab and patients must be vaccinated prior to treatment and monitored throughout. Thus, eculizumab, the first targeted terminal complement inhibitor, provides an effective and generally well tolerated treatment for PNH patients, who have previously been without adequate treatment options.
authors.affiliation: Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Kate
authors.initials: K
authors.lastname: McKeage
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab
references.citation: Blood. 2005 Dec 1;106(12):3699-709
references.pmid: 16051736
references.citation: Korean J Hematol. 2010 Dec;45(4):269-74
references.pmid: 21253430
references.citation: Lancet. 2009 Feb 28;373(9665):759-67
references.pmid: 19144399
references.citation: Circulation. 2004 Apr 20;109(15):1819-22
references.pmid: 15066953
references.citation: Br J Haematol. 1999 Feb;104(2):392-6
references.pmid: 10050724
references.citation: Blood. 2007 Jun 1;109(11):5036-42
references.pmid: 17284529
references.citation: Blood. 2008 Feb 15;111(4):1840-7
references.pmid: 18055865
references.citation: Am J Hematol. 2009 Oct;84(10):699-701
references.pmid: 19705437
references.citation: Haematologica. 2002 Oct;87(10):1095-108
references.pmid: 12368166
references.citation: Int J Hematol. 2011 Jan;93(1):36-46
references.pmid: 21222185
references.citation: Thromb Haemost. 2011 Aug;106(2):383-5
references.pmid: 21655680
references.citation: Blood. 2005 Oct 1;106(7):2559-65
references.pmid: 15985537
references.citation: Exp Hematol. 2007 Apr;35(4):523-33
references.pmid: 17379062
references.citation: Ther Clin Risk Manag. 2009;5:911-21
references.pmid: 20011245
references.citation: Blood. 2011 Jun 23;117(25):6786-92
references.pmid: 21460245
references.citation: Blood. 2007 Dec 1;110(12):4123-8
references.pmid: 17702897
references.citation: Br J Haematol. 2007 May;137(3):181-92
references.pmid: 17408457
references.citation: Haematologica. 2010 Apr;95(4):567-73
references.pmid: 20145265
references.citation: Am J Hematol. 2010 Aug;85(8):553-9
references.pmid: 20658586
references.citation: Br J Haematol. 2010 May;149(3):446-50
references.pmid: 20151973
references.citation: Pediatr Nephrol. 2011 Oct;26(10):1919-20
references.pmid: 21643943
references.citation: Blood. 1981 Jan;57(1):83-9
references.pmid: 7448417
references.citation: JAMA. 2005 Apr 6;293(13):1653-62
references.pmid: 15811985
references.citation: Medicine (Baltimore). 2004 May;83(3):193-207
references.pmid: 15118546
references.citation: N Engl J Med. 2006 Sep 21;355(12):1233-43
references.pmid: 16990386
references.citation: Br J Haematol. 2010 May;149(3):414-25
references.pmid: 20230403
references.citation: Eur J Haematol. 2011 Oct;87(4):376-8
references.pmid: 21623921
references.citation: N Engl J Med. 2004 Feb 5;350(6):552-9
references.pmid: 14762182
references.citation: N Engl J Med. 1995 Nov 9;333(19):1253-8
references.pmid: 7566002
references.citation: Br J Haematol. 2008 Jun;142(2):263-72
references.pmid: 18503589
references.citation: Br J Radiol. 2004 Nov;77(923):953-6
references.pmid: 15507422
references.citation: Nat Biotechnol. 2007 Nov;25(11):1256-64
references.pmid: 17989688
references.citation: Haematologica. 2010 Apr;95(4):523-6
references.pmid: 20378572
references.citation: Haematologica. 2010 Apr;95(4):574-81
references.pmid: 20081060
references.citation: Int J Hematol. 2011 Jun;93(6):704-714
references.pmid: 21611719
references.citation: Leuk Res. 2009 Jun;33(6):e4-5
references.pmid: 18952283
references.citation: Mini Rev Med Chem. 2011 Jun;11(6):528-35
references.pmid: 21561403
references.citation: Am J Transplant. 2011 Nov;11(11):2405-13
references.pmid: 21942930
references.citation: Blood. 2009 Jun 25;113(26):6522-7
references.pmid: 19372253
references.citation: Vaccine. 2009 Jun 24;27 Suppl 2:B51-63
references.pmid: 19477562
references.citation: Thromb Res. 2008;122 Suppl 2:S13-8
references.pmid: 18549907